Early Occurrence of Adverse Events in Hospitalized Patients With COVID-19 and Beneficial Effect of Anticoagulation
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND/AIM: This study analyzed the characteristics of patients with COVID-19 with major events during the first days of hospitalization.
PATIENTS AND METHODS: This is a retrospective analysis of prospectively collected data from consecutive patients admitted to two hospitals in Athens, Greece. The characteristics of patients with COVID-19 who suffered the primary endpoint (venous thromboembolic events, intubation, and death) during the first days of hospitalization were analyzed.
RESULTS: Among 95 patients included in the analysis, 21 presented with major adverse events during a median follow-up of 13 days. More than 50% of these patients presented with a major event during the first 3 days. Anticoagulation treatment was inversely associated with the cumulative incidence of the primary endpoint [hazard ratio=0.16 (95% confidence interval=0.06-0.47)]. Patients with major events were older, with lower baseline SatO2, and higher number of Wells' criteria and Charlson comorbidity index. Among these patients, those with hypertension were at higher risk for early occurrence of events (≤ first three days of hospitalization).
CONCLUSION: Major adverse events may occur early in hospitalized patients with COVID-19 with a high-risk profile. Anticoagulation treatment appears to reduce this risk and thus prompt thromboprophylaxis should be employed in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
In vivo (Athens, Greece) - 36(2022), 1 vom: 31. Jan., Seite 381-383 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dimakakos, Evangelos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 04.01.2022 Date Revised 08.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/invivo.12714 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335082254 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335082254 | ||
| 003 | DE-627 | ||
| 005 | 20231225225043.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/invivo.12714 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM335082254 | ||
| 035 | |a (NLM)34972738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dimakakos, Evangelos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early Occurrence of Adverse Events in Hospitalized Patients With COVID-19 and Beneficial Effect of Anticoagulation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2022 | ||
| 500 | |a Date Revised 08.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a BACKGROUND/AIM: This study analyzed the characteristics of patients with COVID-19 with major events during the first days of hospitalization | ||
| 520 | |a PATIENTS AND METHODS: This is a retrospective analysis of prospectively collected data from consecutive patients admitted to two hospitals in Athens, Greece. The characteristics of patients with COVID-19 who suffered the primary endpoint (venous thromboembolic events, intubation, and death) during the first days of hospitalization were analyzed | ||
| 520 | |a RESULTS: Among 95 patients included in the analysis, 21 presented with major adverse events during a median follow-up of 13 days. More than 50% of these patients presented with a major event during the first 3 days. Anticoagulation treatment was inversely associated with the cumulative incidence of the primary endpoint [hazard ratio=0.16 (95% confidence interval=0.06-0.47)]. Patients with major events were older, with lower baseline SatO2, and higher number of Wells' criteria and Charlson comorbidity index. Among these patients, those with hypertension were at higher risk for early occurrence of events (≤ first three days of hospitalization) | ||
| 520 | |a CONCLUSION: Major adverse events may occur early in hospitalized patients with COVID-19 with a high-risk profile. Anticoagulation treatment appears to reduce this risk and thus prompt thromboprophylaxis should be employed in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a anticoagulation treatment | |
| 650 | 4 | |a high risk factors | |
| 650 | 4 | |a home-treated | |
| 650 | 4 | |a thromboprophylaxis | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Kollias, Anastasios |e verfasserin |4 aut | |
| 700 | 1 | |a Rapti, Vasiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Kyriakoulis, Konstantinos G |e verfasserin |4 aut | |
| 700 | 1 | |a Trontzas, Ioannis P |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelrasoul, Mahmoud M |e verfasserin |4 aut | |
| 700 | 1 | |a Zanelli, Stavroula |e verfasserin |4 aut | |
| 700 | 1 | |a Leontis, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Argyraki, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Dimakou, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Tsoukalas, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Athanasiou, Kalomira |e verfasserin |4 aut | |
| 700 | 1 | |a Nitsotolis, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Syrigos, Konstantinos N |e verfasserin |4 aut | |
| 700 | 1 | |a Poulakou, Garyphallia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t In vivo (Athens, Greece) |d 1992 |g 36(2022), 1 vom: 31. Jan., Seite 381-383 |w (DE-627)NLM012776912 |x 1791-7549 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:1 |g day:31 |g month:01 |g pages:381-383 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/invivo.12714 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 1 |b 31 |c 01 |h 381-383 | ||